patent.fyi
Applications  /  US 2026/0355360
United States Patent Application Publication

US 2026/0355360 A1

Published
Nov 12, 2026
Filed
Jun 24, 2026
Earliest date on the face
Feb 6, 2018
Classification
A61K 51/0459
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

FAP imaging in veterinary oncology

A radiolabeled FAP inhibitor formulation serves as a tracer for veterinary imaging of dogs with solid tumors. A positioning cradle holds the animal in the same position for positron emission tomography and computed tomography. The reconstructed images show tracer uptake in the tumor and surrounding tissues, and serial scans track changes in uptake at the same sites.

Component substitution

Gallium chelate on a quinoline inhibitor

A quinoline-based FAP inhibitor linked to a DOTA chelator serves as the active compound in the diagnostic formulation. The quinoline-based portion binds FAP, and DOTA coordinates gallium-68. A sterile vial contains the labeled compound in a buffered isotonic solution for positron emission tomography.

Parameter or scale variation

Dual time points for tracer imaging

A gallium-68-labeled FAP inhibitor formulation supports two positron emission tomography acquisitions after one administration. The acquisitions start 20 and 60 minutes after administration, each with a 10-minute recording over the same axial field of view. Both reconstructions use the same voxel size and apply decay correction to the administration time. Matched regions yield lesion-to-blood-pool uptake ratios for both time points.

Combination with existing systems

FAP tracer imaging with magnetic resonance

An integrated positron emission tomography and magnetic resonance scanner acquires emission and anatomical data after administration of a radiolabeled FAP inhibitor. A magnetic resonance sequence supplies tissue classes for the attenuation map used in emission reconstruction. The scanner places the reconstructed uptake map and the anatomical images in a common coordinate system for lesion localization.

FAP tracer kit with automated dispensing

A kit contains a sterile source vial of formulated radiolabeled FAP inhibitor, disposable transfer tubing, and dose syringes. A shielded dispensing station connects the source vial to a syringe through a pump and positions the syringe in an activity calibrator. The controller accounts for radioactive decay, checks the measured syringe activity against a preset tolerance, and records the activity and measurement time.

Automated or data-driven variant

Automated measurement of focal tracer uptake

Image analysis software receives reconstructed positron emission tomography and computed tomography images together with administered activity and acquisition timestamps. The software computes standardized uptake values and uses a trained segmentation model to mark candidate regions of focal uptake. It records each region's volume, peak uptake, and ratio to a reference region, then presents the contours for review.

Cite aspatent.fyi, US 2026/0355360 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355360/, SHA-256 6a5713e64861777aae0b3488fe9041cd3cdac038b113769ba269b2e4aa779838
First published
Permanent addresshttps://patent.fyi/US20260355360/
Content fingerprint (SHA-256)6a5713e64861777aae0b3488fe9041cd3cdac038b113769ba269b2e4aa779838
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi